AMDL, Inc. Announces 2009 Financial Guidance and First Quarter Business ...( TUSTIN Calif. Jan. 26 /- AMDL Inc. (N...)

TUSTIN, Calif., Jan. 26 /PRNewswire-FirstCall/ -- AMDL, Inc. (NYSE Alternext US: ADL), a leading vertically integrated bio-pharmaceutical company with operations in the U.S. and China, announced today its fiscal year 2009 preliminary financial guidance and first quarter business objectives.

Fiscal Year 2008 Guidance

AMDL reaffirms its fiscal year 2008 financial guidance of gross revenues in the previously announced range of US$32 million to $36 million, which represents more than a 100% increase over the US$15 million in gross revenues in fiscal year 2007. For fiscal year 2008, AMDL estimates net income after taxes but before foreign currency translation gains of between US$900,000 and $1.3 million. Comprehensive gains after foreign currency translations are estimated to be between US$2.4 and $2.6 million, a downward adjustment that is due to the recently announced equity incentive plan and one-time adjustment for severance payments accrued for AMDL's prior CEO.

Fiscal Year 2009 Preliminary Guidance

AMDL has successfully achieved over 100% gross revenue growth for the past consecutive four years and expects to achieve a comparable gross revenue growth rate for fiscal year 2009 with estimated gross revenues of US$64 million to $72 million and net income between US$8 million and $12 million after taxes and before foreign currency translation gains or losses for its China-based operations only.

This represents an approximate 100% increase in gross revenues over the Company's fiscal year 2008 performance and does not include sales revenue projections for the AMDL ELISA DR-70(R) (FDP) cancer test or export sales for the Company's Human Placental Extract (HPE) anti-aging product line, both of which AMDL anticipates it will begin selling in the second quarter of 2009. AMDL believes anticipated revenues from these two products could potentially re
'/>"/>